Coverage / CRIS / Trade Card

CRIS

Curis Inc

SPECULATIVE BUY 2026-08-01 Updated today USD 5.02 Healthcare - BiotechnologyREDUCE ZONE
42

Position levels

Currenttoday
USD 5.02
Buy <=wait / entry
USD 3.00
Trim >=take some off
USD 4.00
Thesis breakA failure of the lead IRAK4 inhibitor programme in the clinic, a going-concern q...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case8%100 / 1008.0
Base case48%62 / 10029.8
Bear case44%10 / 1004.4
Weighted conviction42 / 100 - SPECULATIVE BUY

Top risks

  • Q1 2026 earnings miss with actual EPS of -$1.25 versus estimate of -$0.27
  • Next earnings report scheduled for Aug 11 2026 with analyst EPS estimate of -$0.34
  • Strong Buy rating from one analyst citing pipeline promise with IRAK4 and FLT3 targeting
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.